Immunic, Inc. (NASDAQ:IMUX) Given Average Recommendation of “Buy” by Analysts

Shares of Immunic, Inc. (NASDAQ:IMUX) have been assigned a consensus recommendation of “Buy” from the eleven brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have given a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $47.5714.

A number of research firms have commented on IMUX. Lifesci Capital raised shares of Immunic to a “strong-buy” rating in a research report on Monday, May 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunic in a research report on Friday, May 29th. Wall Street Zen downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research note on Sunday, April 19th. HC Wainwright reissued a “buy” rating and set a $22.00 price objective (up from $5.00) on shares of Immunic in a report on Thursday, April 30th. Finally, Wolfe Research began coverage on shares of Immunic in a research note on Friday, May 22nd. They issued an “outperform” rating for the company.

Immunic Trading Up 6.0%

Shares of IMUX stock opened at $13.86 on Friday. Immunic has a twelve month low of $5.06 and a twelve month high of $15.77. The stock has a fifty day simple moving average of $11.92 and a two-hundred day simple moving average of $9.44. The stock has a market capitalization of $188.77 million, a price-to-earnings ratio of -2.48 and a beta of 1.37.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.37). Research analysts predict that Immunic will post -4.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Avidity Partners Management LP lifted its stake in shares of Immunic by 42.6% during the 1st quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company’s stock worth $7,436,000 after purchasing an additional 2,000,000 shares during the last quarter. Nantahala Capital Management LLC bought a new position in Immunic in the fourth quarter worth about $2,337,000. Vanguard Group Inc. raised its holdings in Immunic by 5.3% in the third quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock worth $3,832,000 after purchasing an additional 219,957 shares in the last quarter. Laurion Capital Management LP lifted its position in shares of Immunic by 106.3% during the fourth quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock valued at $2,072,000 after buying an additional 2,000,000 shares during the last quarter. Finally, Millennium Management LLC lifted its position in shares of Immunic by 544.6% during the fourth quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock valued at $1,825,000 after buying an additional 2,888,829 shares during the last quarter. 51.82% of the stock is owned by institutional investors.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.